SCHEMBL21752200

SCHEMBL21752200

CC(=O)OCc1nc(Cl)cc2c(C(C)=O)c[nH]c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRPF1 P55201 1/20 0.37
▸ HASPIN Q8TF76 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ PBRM1 Q86U86 1/20 0.33
▸ HSD17B10 Q99714 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ NR4A2 P43354 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ NOTUM Q6P988 1/20 0.30
▸ BCHE P06276 1/20 0.30
▸ ACHE P22303 1/20 0.30
▸ ELANE P08246 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16205349 0.78 BRPF1 (0.47) BRPF1HASPINLMNAPBRM1HSD17B10
SCHEMBL18422483 0.69 ALDH1A1 (0.37) MEN1ALDH1A1HPGDKMT2AKDM4E
SCHEMBL28806403 0.68 PBRM1 (0.50) HASPINLMNAPBRM1HSD17B10MEN1
SCHEMBL21752247 0.66 ALDH1A1 (0.31) ALDH1A1
SCHEMBL6034188 0.66 ALDH1A1 (0.41) LMNAHSD17B10ALDH1A1HPGDCYP1A2
SCHEMBL19644386 0.66 NR4A2 (0.54) LMNAHSD17B10ALDH1A1TP53HPGD
SCHEMBL20487884 0.65 BRPF1 (0.46) BRPF1HASPINLMNAPBRM1HSD17B10
SCHEMBL16964782 0.65 NOTUM (0.38) LMNAHSD17B10MEN1ALDH1A1TP53
SCHEMBL31088121 0.64 ALDH1A1 (0.41) LMNAHSD17B10ALDH1A1HPGDCYP1A2
SCHEMBL4300488 0.64 CYP1A2 (0.63) HSD17B10MEN1ALDH1A1TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841086-B1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2025-04-23 — — EP disclosed
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2023-01-26 — — US disclosed
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2023-01-26 — — US disclosed
EP-3841086-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2021-06-30 — — EP disclosed
WO-2020041301-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2020-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022157-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS CFD, CFH, TFPI BRPF1 2904/4885HASPIN 349/4885LMNA 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback